Shuttle Pharmaceuticals Holdings, Inc. (SHPH)

Market Cap	2.35M
Revenue (ttm)	n/a
Net Income (ttm)	-9.19M
Shares Out	3.66M
EPS (ttm)	-4.29
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	117,242
Open	0.634
Previous Close	0.680
Day's Range	0.605 - 0.680
52-Week Range	0.580 - 4.944
Beta	0.37
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2024

About SHPH

Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatm...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Aug 31, 2022
• Employees: 8
• Stock Exchange: NASDAQ
• Ticker Symbol: SHPH
• Website: https://www.shuttlepharma.com